BlossomHill Therapeutics, Inc.

BlossomHill Therapeutics, Inc. 18 Eylül 2026 tarihinde ne bildirdi

Şirketin kendi 8-K belgesinden.

Kazanç çağrıları

BlossomHill Therapeutics, Inc. için kazanç çağrısı dökümü mevcut değil.

Yönetim ne dedi

“We’ve achieved meaningful progress across our pipeline, as well as our significant corporate milestones, since the beginning of the second quarter,”

Açıklamadan birebir alıntılanmıştır ve yalnızca belge sözü adı geçen bir kişiye atfettiğinde gösterilir.

Fiyat nasıl tepki verdi

Açıklamalar kapanıştan sonra ya da açılıştan önce gelir, dolayısıyla hareket bir sonraki seansa aittir.

BlossomHill Therapeutics, Inc. ne yapar

BH-30643 is an investigational, novel, orally bioavailable, non-covalent, macrocyclic, brain active, mutant-selective, OMNI-EGFR ™ inhibitor for the treatment of EGFR -mutant NSCLC. BH-30643 was designed to overcome the limitations of currently approved EGFR inhibitors, which were discovered over a decade ago without the current, modern understanding of the structure and protein dynamics of mutant EGFRs. In preclinical studies, BH-30643 demonstrated potent inhibitory activity across diverse EGFR mutation categories – classical mutations, on-target resistance mutations such as C797S with or without T790M, atypical mutations and exon 20 insertions – while maintaining marked selectivity over wild-type EGFR. BH-30643 has received Fast Track designation and is being evaluated in SOLARA, a global Phase 1/2, first-in-human clinical trial spanning more than 40 sites in 10 countries. Ongoing dose expansion cohorts are enrolling in both TKI-pretreated and TKI-naive settings, including a C797S resistance cohort. For additional information on SOLARA, including a list of study sites and how to enroll, please visit clinicaltrials.gov ( NCT06706076 ).

Şirketin kendi tanımı, açıklamanın sonunda göründüğü hâliyle.